About Human CD8α Recombinant Protein

CD8α (CD8A) is a type I transmembrane glycoprotein expressed primarily on cytotoxic T lymphocytes (CD8⁺ T cells) and a subset of natural killer (NK) cells. CD8 functions as a co-receptor for the T-cell receptor (TCR) by binding to major histocompatibility complex class I (MHC I) molecules on antigen-presenting or target cells, thereby enhancing T-cell activation, antigen recognition, and cytotoxic immune responses. CD8 exists as either a CD8αα homodimer or the physiologically predominant CD8αβ heterodimer, both of which play essential roles in adaptive immunity.

eEnzyme's Human CD8α Recombinant Protein is produced for research use and is suitable for studies of T-cell biology, immune checkpoint research, receptor-ligand interactions, antibody development, ELISA, flow cytometry assay development, and immunotherapy research. This recombinant protein provides a valuable reagent for investigating T-cell activation, antigen recognition, and cellular immune responses.

Applications

Biological Significance of CD8α

CD8α is a critical co-receptor that enhances T-cell receptor signaling during antigen recognition by stabilizing interactions between cytotoxic T cells and MHC class I-presented antigens. Through its association with the Src family kinase Lck, CD8α amplifies intracellular signaling required for T-cell activation, proliferation, and cytotoxic function. Because CD8⁺ T cells are central to antiviral immunity, tumor surveillance, and immunotherapy, CD8α has become an important target for studies of adaptive immunity, cancer immunology, infectious diseases, and T-cell-based therapeutic development. The Human CD8α Recombinant Protein provides a valuable tool for investigating immune regulation and supporting the development of next-generation immunotherapies.